@article { author = {}, title = {Pemetrexed in Treating Patients with Metastatic Bladder Cancer}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {16}, number = {9}, pages = {3839-3841}, year = {2015}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Background: This pooled analysis was conducted to evaluate the efficacy and safety of pemetrexed basedchemotherapy in treating patients with metastatic bladder cancer as salvage chemotherapy. Methods: Clinicalstudies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients withbladder cancer were identified by using a predefined search strategy. Pooled response rate (RR) of treatmentwere calculated. Results: In pemetrexed based regimens, 3 clinical studies which including 105 patients withadvanced transitional cell cancer of the urothelium were considered eligible for inclusion. Pooled analysissuggested that, in all patients, pooled RR was 26.7% (28/105) for pemetrexed based regimens. Major adverseeffects were neutropenia, anorexia, fatigue, and anemia in pemetrexed based treatment. Two treatment relateddeaths occurred with pemetrexed based treatment. Conclusion: This pooled analysis suggests that pemetrexedbased regimens are associated with mild activity and good tolerability in treating patients with metastatic bladdercancer.}, keywords = {Pemetrexed,metastatic bladder cancer}, url = {https://journal.waocp.org/article_30997.html}, eprint = {https://journal.waocp.org/article_30997_f53f3e04686d22504cc6147c6229e86e.pdf} }